Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4571 Characterisation and prognostic impact of carcinoid syndrome in bronchial neuroendocrine tumours

Introduction: Metastatic bronchial neuroendocrine tumours (MBNET) are associated with carcinoid syndrome in 10 to 40% of cases. Characteristics of carcinoid heart disease (CHD) are poorly described.

Conference:

Presenting Author: Baudin E

Authors: Hescot S, Marret G, Hadoux J, Laboureau S, Haissaguerre M,

Keywords: bronchial NET, carcinoid syndrome, 5HIAA, carcinoid heart disease,

#3420 Etoposide-based rechallenge and second/third line treatments in patients with metastatic neuroendocrine carcinoma: Results from the multicenter RBNEC study of the Groupe d’Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network

Introduction: Neuroendocrine carcinomas (NEC) are aggressive malignant diseases. Etoposide-based rechallenge (EBR) and the prognostic role of Rb status in second-line (SL) have not been studied.

Conference:

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Walter T, Hescot S, Hautefeuille V,

Keywords: Neuroendocrine carcinoma, Rb, rechallenge,

#3136 Prognosis and the role of Rb expression in metastatic grade 3 neuroendocrine carcinoma (G3NEC), results from the multicenter retrospective RbNEC study

Introduction: Rb has been suggested to be a predictive/prognostic factor in G3NEC in which platinum etoposide (PE) is the first line treatment whatever primary.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Durand A, Hescot S, Hautefeuille V,

Keywords: neuroendocrine carcinoma, g3, Rb, prognosis,